Recherchiere Firmenbekanntmachungen und finanzielle Kennzahlen
EU-Förderung (2.629.316 €): Translational Research Network in Prostatakrebs Hor26.09.2016 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Text
Translational Research Network in Prostatakrebs
The Translational Research Network for Prostate Cancer (TransPot) program adopts an innovative, multidisciplinary approach, providing highly sought-after, effective solutions for incurable prostate cancer (PC). The TransPot scientific objective is to obtain an unmatched depth of molecular, mechanistic and informatics systems-level disease understanding in order to improve the prognosis and treatment of lethal PC, aimed to (i) provide important insights into molecular mechanisms driving treatment resistant PC including castrate-resistant PC (CRPC), (ii) identify novel therapeutic targets, (iii) develop and validate predictive models for disease progression, prognosis and responsiveness to current and novel (co-)treatment options, and (iv) provide superior, clinically relevant tools and biomarker signatures for personalising and optimising CRPC therapy. Our research program is built on network-wide, state-of-the-art cancer biology-based mechanistic research integrated with a systems medicine approach: 1. Cancer biology-based mechanistic research incorporating a comprehensive range of model systems incorporating unique, pre-clinical and clinical resources and distinct phenotypic high content screen platforms. 2. A systems medicine approach with mathematical modelling to develop novel predictive/prognostic tools. 3. Centres of excellence in surgery, oncology and clinical trials, comprising clinical infrastructure and essential resources whereby candidate therapeutic targets and predictive/prognostic tools can be comprehensively evaluated, including accessing bio-repository resources. We will train young scientists to apply multiple ‘omics’ technologies and approaches in model systems and systems biology to answer important clinically-relevant questions. Advances achieved will facilitate personalized targeted-medicine in treating lethal PC, and will impact beyond the scientific community by improving the well-being of advanced PC patients.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| ? | |
| Almac Diagnostic Services Ltd. | 273.288 € |
| Erasmus Universitair Medisch Centrum Rotterdam | 255.374 € |
| 319.218 € | |
| 242.387 € | |
| MOSAIQUES DIAGNOSTICS GmbH | 0,00 € |
| NUMARES AG | 249.216 € |
| 269.145 € | |
| TURUN YLIOPISTO | 269.145 € |
| The Queen's University of Belfast | 204.966 € |
| University of Glasgow | 273.288 € |
| University of Newcastle Upon Tyne | 273.288 € |
Quelle: https://cordis.europa.eu/project/id/721746
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider. Der aktuelle Stand wird auf folgender Seite wiedergegeben: Cancer Research UK LBG, London, Großbritannien.
Die Visualisierungen zu "Cancer Research UK LBG - EU-Förderung (2.629.316 €): Translational Research Network in Prostatakrebs"
werden von
North Data
zur Weiterverwendung unter einer
Creative Commons Lizenz
zur Verfügung gestellt.
